Status:
TERMINATED
Hong Kong and Taiwan HM3 PMS
Lead Sponsor:
Abbott Medical Devices
Conditions:
Advanced Heart Failure
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Hong Kong and Taiwan HM3 PMS is a prospective, single arm, post market surveillance is designed to evaluate clinical and functional outcomes with the HM3 LVAS as a treatment for advanced heart failure...
Eligibility Criteria
Inclusion
- \- All patients at the participating sites that are determined to meet the HM3 commercially approved labelling indication and have a planned HM3 implant are eligible to participate in this PMS. Assessment for eligibility criteria is based on medical records of the site and interview with a candidate patient.
Exclusion
- None
Key Trial Info
Start Date :
July 14 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2022
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT04703855
Start Date
July 14 2021
End Date
June 30 2022
Last Update
July 1 2024
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Hong Kong
Hong Kong, Pokfulam, Hong Kong
2
National Taiwan University Hospital
Taipei, Taiwan, 100
3
Tri-Service General Hospital
Taipei, Taiwan, 114